Get the Stockscreener App
9.75
0.52%
0.05
After Hours:
9.56
-0.19
-1.95%
Meiragtx Holdings Plc stock is traded at $9.75, with a volume of 480.41K.
It is up +0.52% in the last 24 hours and up +6.21% over the past month.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
See More
Previous Close:
$9.70
Open:
$9.86
24h Volume:
480.41K
Relative Volume:
0.75
Market Cap:
$902.59M
Revenue:
$81.39M
Net Income/Loss:
$-114.20M
P/E Ratio:
-6.8407
EPS:
-1.4253
Net Cash Flow:
$-50.60M
1W Performance:
+7.38%
1M Performance:
+6.21%
6M Performance:
+13.64%
1Y Performance:
+51.16%
1-Day Range:
$9.63
$10.08
1-Week Range:
$8.75
$10.08
52-Week Range:
$4.55
$11.85
Meiragtx Holdings Plc Stock (MGTX) Company Profile
Name
Meiragtx Holdings Plc
Sector
Industry
Phone
646-860-7985
Address
655 THIRD AVENUE, NEW YORK, NY
Compare MGTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGTX
Meiragtx Holdings Plc
|
9.75 | 897.96M | 81.39M | -114.20M | -50.60M | -1.4253 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Meiragtx Holdings Plc Stock (MGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-31-24 | Resumed | Chardan Capital Markets | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Sep-15-20 | Resumed | BofA Securities | Buy |
| Sep-03-19 | Initiated | Piper Jaffray | Overweight |
| Feb-27-19 | Reiterated | Chardan Capital Markets | Buy |
| Jul-03-18 | Initiated | Barclays | Overweight |
| Jul-03-18 | Initiated | BofA/Merrill | Buy |
View All
Meiragtx Holdings Plc Stock (MGTX) Latest News
Will MeiraGTx Holdings PLC (MGTX) report negative Q1 earnings? What you should know - MSN
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
MeiraGTx Holdings plc ($MGTX) President and CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] MeiraGTx Holdings plc SEC Filing - Stock Titan
MeiraGTx (NASDAQ: MGTX) details pay and board votes for 2026 AGM - Stock Titan
MeiraGTx (MGTX) CMO amends Form 4 for 7,814 tax-withheld shares - Stock Titan
MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle? - MSN
MeiraGTx rises on upcoming phase 1 readout for gene therapy - MSN
DAVENPORT & Co LLC Purchases 7,000 Shares of MeiraGTx Holdings Plc (NASDAQ:MGTX) - 富途牛牛
Discipline and Rules-Based Execution in MGTX Response - Stock Traders Daily
Eli Lilly partner MeiraGTx regains rights for genetic eye disease drug from Johnson & Johnson - MSN
MeiraGTx Holdings PLC (MGTX) Q4 earnings and revenues surpass estimates - MSN
Here is Why MeiraGTx Holdings (MGTX) is One of the Best Growth Stocks Under $10 - Yahoo Finance
Perceptive lifts MeiraGTx (NASDAQ: MGTX) ownership to 12.6% with warrants - Stock Titan
MeiraGTx and Hologen Enter Material Definitive Agreements and Collaboration License for Neuro AI – April 2026 - Minichart
MeiraGTx and Hologen finalize collaboration and licensing agreements By Investing.com - Investing.com Nigeria
MeiraGTx and Hologen finalize collaboration and licensing agreements - Investing.com
MeiraGTx acquires J&J's XLRP investigational therapy - Eyes On Eyecare
MeiraGTx (NASDAQ: MGTX) details $200M Hologen CNS gene therapy pact - Stock Titan
MeiraGTx (MGTX) Perceptive funds gain $8 warrants and new shares - Stock Titan
Piper Sandler raises MeiraGTx stock price target to $30 on data By Investing.com - Investing.com Australia
MGTX Maintained by Piper Sandler -- Price Target Raised to $30 - GuruFocus
Piper Sandler raises MeiraGTx stock price target to $30 on data - Investing.com UK
MeiraGTx (NASDAQ:MGTX) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
What is HC Wainwright's Forecast for MeiraGTx Q1 Earnings? - MarketBeat
Piper Sandler Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Raises Target Price to $30 - Moomoo
MGTX SEC FilingsMeiragtx Holdings Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Richard Giroux Sells 56,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock - MarketBeat
MeiraGTx CFO & COO Richard Giroux sells $572,320 in stock By Investing.com - Investing.com South Africa
MeiraGTx CFO & COO Richard Giroux sells $572,320 in stock - Investing.com
[144] MeiraGTx Holdings plc SEC Filing - Stock Titan
MeiraGTx (MGTX) CFO sells 56,000 shares under 10b5-1 plan - Stock Titan
Genetic Medicines Co. Reveals Transformative 'Only-of-Its-Kind' AAV Therapy Milestone - Streetwise Reports
Latham & Watkins Represents MeiraGTx in US$100 Million Ordinary Shares Offering - Latham & Watkins LLP
MEIRAGTX HOLDINGS PLC : COMPANY ANNOUNCEMENT - marketscreener.com
H.C. Wainwright reiterates MeiraGTx stock rating on gene therapy progress By Investing.com - Investing.com India
H.C. Wainwright reiterates MeiraGTx stock rating on gene therapy progress - Investing.com
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock? - Yahoo Finance
H.C. Wainwright Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
MeiraGTx Announces Public Equity Offering to Fund Growth - The Globe and Mail
MGTX Maintained by RBC Capital -- Price Target Raised to $24.00 - GuruFocus
Meiragtx Holdings Plc Stock (MGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):